The value of serum amyloid A for predicting the severity and recovery of COVID19
The present study aimed to evaluate the value of serum amyloid A (SAA) in coronavirus disease 2019 (COVID19) and compared the efficacy of SAA and Creactive protein (CRP) in predicting the severity and recovery of COVID19. A retrospective study was conducted on COVID19 patients hospitalized
in Wuhan No. 1 Hospital (Hubei, China) from January 21, 2020 to March 4, 2020. A twoway ANOVA analysis was used to compare the serum CRP and SAA levels between mild group and severe group during hospitalization days. Linear regression was used to analyze the relationship between the serum
CRP, SAA levels and treatment days in recovered patients. The Logistic regression analysis and the area under curve (AUC) were calculated to determine the probability for predicting the severity and recovery of COVID19. The severe group displayed higher CRP and SAA levels compared with the
mild group during hospitalization (P<0.001). Logistic regression indicated that SAA and CRP were independent risk factors for the severity of COVID19. The corresponding AUC of CRP and SAA values for severity of COVID19 were 0.804 and 0.818, respectively. Linear regression analysis revealed
that CRP and SAA levels were negatively correlated with treatment days in recovered patients (r=0.761, 0.795, respectively). Logistic regression demonstrated that SAA was an independent factor for predicting the recovery of COVID19. However, CRP could not predict the recovery of COVID19. The
corresponding AUC of SAA for the recovery of COVID19 was 0.923. The results of the present study indicated that SAA can be considered to be a biomarker for predicting the severity and recovery of COVID19.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Radiology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Department of Geriatrics, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Department of Clinical Laboratory, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites